최소 단어 이상 선택하여야 합니다.
최대 10 단어까지만 선택 가능합니다.
다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
NTIS 바로가기약학회지 = Yakhak hoeji, v.62 no.3, 2018년, pp.158 - 170
신석호 (충남대학교 약학대학) , 박민호 (충남대학교 약학대학) , 변진주 (충남대학교 약학대학) , 이병일 (충남대학교 약학대학) , 박유리 (충남대학교 약학대학) , 최장미 (충남대학교 약학대학) , 김나혜 (충남대학교 약학대학) , 신영근 (충남대학교 약학대학)
The antibody-drug conjugate (ADC) is one of the most rapidly growing next generation antibody therapies used in oncology, autoimmunity and chronic inflammatory diseases. ADC is consisted of monoclonal antibody conjugated via chemical linker with highly cytotoxic small molecules, called payloads. Due...
Next-generation antibody therapies market forecast pp. Visiongain. (2016).
Hoffmann, R. M., Coumbe, B. G. T., Josephs, D. H., Mele, S., Ilieva, K. M., Cheung, A., Tutt, A. N., Spicer, J. F., Thurston, D. E., Crescioli, S. and Karagiannis, S. N. : Antibody structure and engineering considerations for the design and function of Antibody Drug Conjugates (ADCs). Oncoimmunology 7, e1395127 (2018).
Jain, N., Smith, S. W., Ghone, S., Tomczuk, B. : Current ADC Linker Chemistry. Pharm Res 32, 3526 (2015).
Masters, J. C., Nickens, D. J., Xuan, D., Shazer, R. L., Amantea, M. : Clinical toxicity of antibody drug conjugates: a meta-analysis of payloads. Invest New Drugs 36, 121 (2018).
Lo-Coco, F., Cimino, G., Breccia, M., Noguera, N. I., Diverio, D., Finolezzi, E., Pogliani, E. M., Di Bona, E., Micalizzi, C., Kropp, M., Venditti, A., Tafuri, A., Mandelli, F. : Gemtuzumab ozogamicin (Mylotarg) as a single agent for molecularly relapsed acute promyelocytic leukemia. Blood 104, 1995 (2004).
Parigger, J., Zwaan, C. M., Reinhardt, D., Kaspers, G. J. : Dose-related efficacy and toxicity of gemtuzumab ozogamicin in pediatric acute myeloid leukemia. Expert Rev Anticancer Ther 16, 137 (2016).
Bartlett, N. L., Chen, R., Fanale, M. A., Brice, P., Gopal, A., Smith, S. E., Advani, R., Matous, J. V., Ramchandren, R., Rosenblatt, J. D., Huebner, D., Levine, P., Grove, L., Forero-Torres, A. : Retreatment with brentuximab vedotin in patients with CD30-positive hematologic malignancies. J Hematol Oncol 7, 24 (2014).
Prince, H. M., Kim, Y. H., Horwitz, S. M., Dummer, R., Scarisbrick, J., Quaglino, P., Zinzani, P. L., Wolter, P., Sanches, J. A., Ortiz-Romero, P. L., Akilov, O. E., Geskin, L., Trotman, J., Taylor, K., Dalle, S., Weichenthal, M., Walewski, J., Fisher, D., Dreno, B., Stadler, R., Feldman, T., Kuzel, T. M., Wang, Y., Palanca-Wessels, M. C., Zagadailov, E., Trepicchio, W. L., Zhang, W., Lin, H. M., Liu, Y., Huebner, D., Little, M., Whittaker, S., Duvic, M. : Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial. Lancet 390, 555 (2017).
Suri, A., Mould, D. R., Liu, Y., Jang, G., Venkatakrishnan, K. : Population PK and Exposure-Response Relationships for the Antibody-Drug Conjugate Brentuximab Vedotin in CTCL Patients in the Phase III ALCANZA Study. Clin Pharmacol Ther (2018).
Jhaveri, K. : MARIANNE: Impact on Current Treatment of Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer and Implications for the Future. J Clin Oncol 35, 127 (2017).
Baselga, J., Lewis Phillips, G. D., Verma, S., Ro, J., Huober, J., Guardino, A. E., Samant, M. K., Olsen, S., de Haas, S. L., Pegram, M. D. : Relationship between Tumor Biomarkers and Efficacy in EMILIA, a Phase III Study of Trastuzumab Emtansine in HER2-Positive Metastatic Breast Cancer. Clin Cancer Res 22, 3755 (2016).
Martinez, M. T., Perez-Fidalgo, J. A., Martin-Martorell, P., Cejalvo, J. M., Pons, V., Bermejo, B., Martin, M., Albanell, J., Lluch, A. : Treatment of HER2 positive advanced breast cancer with T-DM1: A review of the literature. Crit Rev Oncol Hematol 97, 96 (2016).
Kim, S. B., Wildiers, H., Krop, I. E., Smitt, M., Yu, R., Lysbet de Haas, S., Gonzalez-Martin, A. : Relationship between tumor biomarkers and efficacy in TH3RESA, a phase III study of trastuzumab emtansine (T-DM1) vs. treatment of physician's choice in previously treated HER2-positive advanced breast cancer. Int J Cancer 139, 2336 (2016).
Castaigne, S., Pautas, C., Terre, C., Raffoux, E., Bordessoule, D., Bastie, J. N., Legrand, O., Thomas, X., Turlure, P., Reman, O., de Revel, T., Gastaud, L., de Gunzburg, N., Contentin, N., Henry, E., Marolleau, J. P., Aljijakli, A., Rousselot, P., Fenaux, P., Preudhomme, C., Chevret, S., Dombret, H. : Acute Leukemia French, A., Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study. Lancet 379, 1508 (2012).
Amadori, S., Suciu, S., Selleslag, D., Aversa, F., Gaidano, G., Musso, M., Annino, L., Venditti, A., Voso, M. T., Mazzone, C., Magro, D., De Fabritiis, P., Muus, P., Alimena, G., Mancini, M., Hagemeijer, A., Paoloni, F., Vignetti, M., Fazi, P., Meert, L., Ramadan, S. M., Willemze, R., de Witte, T., Baron, F. : Gemtuzumab Ozogamicin Versus Best Supportive Care in Older Patients With Newly Diagnosed Acute Myeloid Leukemia Unsuitable for Intensive Chemotherapy: Results of the Randomized Phase III EORTC-GIMEMA AML-19 Trial. J Clin Oncol 34, 972 (2016).
Pilorge, S., Rigaudeau, S., Rabian, F., Sarkozy, C., Taksin, A. L., Farhat, H., Merabet, F., Ghez, S., Raggueneau, V., Terre, C., Garcia, I., Renneville, A., Preudhomme, C., Castaigne, S., Rousselot, P. : Fractionated gemtuzumab ozogamicin and standard dose cytarabine produced prolonged second remissions in patients over the age of 55 years with acute myeloid leukemia in late first relapse. Am J Hematol 89, 399 (2014).
Kantarjian, H. M., DeAngelo, D. J., Stelljes, M., Martinelli, G., Liedtke, M., Stock, W., Gokbuget, N., O'Brien, S., Wang, K., Wang, T., Paccagnella, M. L., Sleight, B., Vandendries, E., Advani, A. S. : Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia. N Engl J Med 375, 740 (2016).
https://pharmaphorum.com/news/nice-reassess-pfizer-blood-cancer-drug/
Anderl, J., Faulstich, H., Hechler, T., Kulke, M. : Antibody-drug conjugate payloads. Methods Mol Biol 1045, 51 (2013).
Lu, J., Jiang, F., Lu, A., Zhang, G. : Linkers Having a Crucial Role in Antibody-Drug Conjugates. Int J Mol Sci 17, 561 (2016).
Junutula, J. R. and Gerber, H. P. : Next-Generation Antibody-Drug Conjugates (ADCs) for Cancer Therapy. ACS Med Chem Lett 7, 972 (2016).
Carter, P. J. and Senter, P. D. : Antibody-drug conjugates for cancer therapy. Cancer J 14, 154 (2008).
Ross, P. L. and Wolfe, J. L. : Physical and Chemical Stability of Antibody Drug Conjugates: Current Status. J Pharm Sci 105, 391 (2016).
Hinrichs, M. J., Dixit, R. : Antibody Drug Conjugates: Nonclinical Safety Considerations. AAPS J 17, 1055 (2015).
Strop, P., Delaria, K., Foletti, D., Witt, J. M., Hasa-Moreno, A., Poulsen, K., Casas, M. G., Dorywalska, M., Farias, S., Pios, A., Lui, V., Dushin, R., Zhou, D., Navaratnam, T., Tran, T. T., Sutton, J., Lindquist, K. C., Han, B., Liu, S. H., Shelton, D. L., Pons, J., Rajpal, A. : Site-specific conjugation improves therapeutic index of antibody drug conjugates with high drug loading. Nat Biotechnol 33, 694 (2015).
Zhao, H., Peng, P., Longley, C., Zhang, Y., Borowski, V., Mehlig, M., Reddy, P., Xia, J., Borchard, G., Lipman, J., Benimetskaya, L., Stein, C. A. : Delivery of G3139 using releasable PEG-linkers: impact on pharmacokinetic profile and anti-tumor efficacy. J Control Release 119, 143 (2007).
Connors, J. M., Jurczak, W., Straus, D. J., Ansell, S. M., Kim, W. S., Gallamini, A., Younes, A., Alekseev, S., Illes, A., Picardi, M., Lech-Maranda, E., Oki, Y., Feldman, T., Smolewski, P., Savage, K. J., Bartlett, N. L., Walewski, J., Chen, R., Ramchandren, R., Zinzani, P. L., Cunningham, D., Rosta, A., Josephson, N. C., Song, E., Sachs, J., Liu, R., Jolin, H. A., Huebner, D., Radford, J., Group, E.-S. : Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin's Lymphoma. N Engl J Med 378, 331 (2018).
Wang, E. S., Ades, L., Fathi, A. T., Kreuzer, K. A., O'Meara, M. M., Liang, S.-Y., Ravandi, F. : CASCADE: A phase 3, randomized, double-blind study of vadastuximab talirine (33A) versus placebo in combination with azacitidine or decitabine in the treatment of older patients with newly diagnosed acute myeloid leukemia (AML). Journal of Clinical Oncology 35, TPS7066 (2017).
Moore, K. N., Vergote, I., Oaknin, A., Colombo, N., Banerjee, S., Oza, A., Pautier, P., Malek, K., Birrer, M. J. : FORWARD I: a Phase III study of mirvetuximab soravtansine versus chemotherapy in platinum-resistant ovarian cancer. Future Oncol (2018).
Moore, K. N., Martin, L. P., O'Malley, D. M., Matulonis, U. A., Konner, J. A., Perez, R. P., Bauer, T. M., Ruiz-Soto, R., Birrer, M. J., Safety and Activity of Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha-Targeting Antibody-Drug Conjugate, in Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer: A Phase I Expansion Study. J Clin Oncol 35, 1112 (2017).
Coiffier, B., Thieblemont, C., de Guibert, S., Dupuis, J., Ribrag, V., Bouabdallah, R., Morschhauser, F., Navarro, R., Le Gouill, S., Haioun, C., Houot, R., Casasnovas, O., Holte, H., Lamy, T., Broussais, F., Payrard, S., Hatteville, L., Tilly, H. : A phase II, single-arm, multicentre study of coltuximab ravtansine (SAR3419) and rituximab in patients with relapsed or refractory diffuse large B-cell lymphoma. Br J Haematol 173, 722 (2016).
Ocean, A. J., Starodub, A. N., Bardia, A., Vahdat, L. T., Isakoff, S. J., Guarino, M., Messersmith, W. A., Picozzi, V. J., Mayer, I. A., Wegener, W. A., Maliakal, P., Govindan, S. V., Sharkey, R. M., Goldenberg, D. M. : Sacituzumab govitecan (IMMU-132), an anti-Trop-2-SN-38 antibody-drug conjugate for the treatment of diverse epithelial cancers: Safety and pharmacokinetics. Cancer 123, 3843 (2017).
Dotan, E., Cohen, S. J., Starodub, A. N., Lieu, C. H., Messersmith, W. A., Simpson, P. S., Guarino, M. J., Marshall, J. L., Goldberg, R. M., Hecht, J. R., Wegener, W. A., Sharkey, R. M., Govindan, S. V., Goldenberg, D. M., Berlin, J. D. : Phase I/II Trial of Labetuzumab Govitecan (Anti-CEACAM5/SN-38 Antibody-Drug Conjugate) in Patients With Refractory or Relapsing Metastatic Colorectal Cancer. J Clin Oncol 35, 3338 (2017).
Burris, H. A., Barve, M. A., Hamilton, E. P., Bardia, A., Soliman, H. H., Jarlenski, D., Mosher, R, Bergstrom, D. A. : A phase Ib, first-in-human, dose escalation and expansion study of XMT-1522, a novel antibody-drug conjugate (ADC) directed against HER2, in patients with advanced breast cancer and other advanced tumors expressing HER2. Journal of Clinical Oncology 35, TPS2606 (2017).
*원문 PDF 파일 및 링크정보가 존재하지 않을 경우 KISTI DDS 시스템에서 제공하는 원문복사서비스를 사용할 수 있습니다.
오픈액세스 학술지에 출판된 논문
※ AI-Helper는 부적절한 답변을 할 수 있습니다.